Neurotropin® alleviates nerve damage in a mouse chronic nerve compression model.

Chronic nerve compression disorders, such as carpal tunnel syndrome, are common and can significantly impair daily activities due to motor and sensory dysfunctions. Currently, no systemic pharmacotherapy exists for preventing or treating disease progression. This study aims to investigate whether Neurotropin®, an established analgesic, has therapeutic effects.

Methylcobalamin-containing nanofiber sheets have better neuroprotective effects than small intestinal submucosa sheets.

Postoperative adhesion around nerves sometimes results in sensory and motor dysfunctions. To prevent these disorders, we have developed an electrospun nanofiber sheet incorporating methylcobalamin (MeCbl), an active form of vitamin B12 with anti-inflammatory and neuroregenerative effects. This study aimed to investigate the neuroprotective effects of MeCbl sheets against postoperative adhesion and to compare the effects of MeCbl sheets with those of porcine small intestinal submucosa (SIS) sheets using a rat sciatic nerve adhesion model.

PDPN/CLEC-2 axis modulates megakaryocyte subtypes in a hematopoietic stem cell-regulating megakaryocyte-dominant manner.

Introduction: Megakaryocytes are classified into several subtypes including LSP1-positive immune-skewed, MYLK4-positive hematopoietic stem cell (HSC)-regulating, and BMAL1-positive platelet-producing megakaryocytes. Podoplanin (PDPN)-expressing stromal cells generate a microenvironment that promotes megakaryopoiesis in the bone marrow. In this context, PDPN interacts with C-type lectin-like receptor-2 (CLEC-2) on megakaryocyte progenitors, which induces megakaryocyte proliferation.

Pandemic risk characterisation of zoonotic influenza A viruses using the Tool for Influenza Pandemic Risk Assessment (TIPRA).

A systematic risk assessment approach is essential for evaluating the relative risk of influenza A viruses (IAVs) with pandemic potential. To achieve this, the Tool for Influenza Pandemic Risk Assessment (TIPRA) was developed under the Global Influenza Programme of WHO. Since its release in 2016 and update in 2020, TIPRA has been used to assess the pandemic risk of 11 zoonotic IAVs across ten evaluation rounds.